# BioDiem

## Therapies for major infectious diseases and related cancers

Australia Biotech Invest 2013 : Melbourne 28 October 2013

Julie Phillips, CEO www. biodiem.com (ASX:BDM)

## BioDiem Agenda





**Company Focus** 



**Current Achievements** 



**Future Investment Opportunity** 

## BioDiem Challenges



To antibiotics – major concern healthcare systems worldwide



#### Hard to treat

Fungal infections, affecting vulnerable patients



#### No vaccines available

For worldwide diseases e.g. therapeutic vaccines for hep B, C and D




#### **Product pipelines diminish**


Large Pharma focus on innovation, as product pipelines diminish > acquisition opportunities

## BioDiem Company Focus


## BioDiem Business Model



## BioDiem Business Model



## BioDiem Business Model



## BioDiem Three core development programs

Target	<b>B</b> Core Technology
Influenza vaccines (seasonal and pandemic)	✦ LAIV vaccine − licensed in multiple countries
Vaccine development platforms Hepatitis B/D, nasopharyngeal carcinoma, TB	<ul> <li>Hepatitis vaccine technology, LAIV</li> <li>viral vector, flavivirus and SAVINE</li> <li>technologies for novel therapeutic</li> <li>vaccines</li> </ul>
Infectious disease therapies Fungal disease: difficult to treat Bacterial disease: MRSA Parasites: Schistosomiasis	BDM-I antimicrobial compound

## BioDiem Influenza Vaccines

#### Live Attenuated Influenza Virus: LAIV

**Advantages** 



#### Needle-free nasal delivery

No trained personnel and blood/sharps precautions unnecessary



#### **Broader immune response**

Than seen with inactivated influenza vaccines



#### No adjuvant required



#### Extensive clinical and market experience > 100m doses

In Russia efficacy and safety in >500,000 adults/140,000 children



#### High yields

In egg-based or cell-based production (with no reliance on eggs)

## BioDiem Flu vaccines

#### Live Attenuated Influenza Virus: LAIV

Product	Disease Targets	Current Partners	Development Status
LAIV	Influenza – Seasonal & Pandemic	WHO SII (India) BCHT (China) IEM (Russia)	Marketed with license revenues \$A1.3m FY2012 Phase II (cell-based technology) Seeking growth & out-licensing in more markets
(Influenza)	Avian (Bird) Flu	IEM/WHO	Clinical trials completed in Thailand and Russia

## BioDiem Vaccine development platforms


#### **Opportunity to target multiple infectious diseases and related cancers**





Disease Targets	Vaccine development	Nasopharyngeal carcinoma (NPC), tuberculosis (TB)	
Current Partners	VALNEVA (previously known as VIVALIS)	In-house	
Development Status	First stage of development project completed	Seeking partner for more advanced data in animals	

### BioDiem Hepatitis Vaccine (therapeutic)



Rights licensed from the University of Canberra

R&D program underway

Proof-of-principle demonstrated (July 2013)

## BioDiem Infectious disease therapies

\*\* \*\*\*\*\*\*\*

## BioDiem BDM-I antimicrobial disease targets

BDM-I currently in development as treatment against

- 'superbugs' such as antibiotic-resistant bacteria incl. TB, and others
- hard-to-treat fungal infections

Product	Disease Targets	Current Partners	Development Status
	Bacterial infections (tuberculosis, others)	US government backed research institutions	Entered <i>in vivo</i> testing in 2013; formulation development underway
BDM-I (Antimicrobial)	Fungal infections	US government backed research institutions	Entered <i>in vivo</i> testing in 2013; formulation development underway
	Parasitic diseases (schistosomiasis, others)	QIMR program	Entered <i>in vivo</i> testing in 2013; formulation development underway

## Expanding Global Partnerships and Alliances

#### **Global partnering & commercialisation network**

PATH • USAMRIID

BioDiem

BioReliance VALNEVA • • WHO

**9** National Institutes of Health

Centres for Disease Control

Institute of Experimental Medicine

**9** BCHT

Serum Institute of India

QLD Institute of Medical Research Australian National University University of Canberra RMIT Griffith University

## BioDiem Current Achievements

#### **Vaccine Development Pipeline**

	Research	Preclinical	Phase I	Phase II	Phase III	Marketed
Influenza vaccines (Seasonal & Pandemic)	Cell based production Egg based production					
		alth Organisation for pu titute of India and Char			eveloping Country p	rivate markets
<b>LAIV</b> Viral Vector platform						
Hepatitis D PLATFORM (Hepatitis D/Hepatitis B therapeutic vaccine)						
Flavivirus PLATFORM (Dengue fever, West Nile, Murray River encephalitis)						
SAVINE antigen technology (Tuberculosis, NPC)						

### BioDiem Current Achievements cont'd

#### **BDM-I** Development Pipeline

	Research	Preclinical	Phase I	Phase II	Phase III	On market
<b>Bacterial targets</b> (Biological warfare agents, MSRA, tuberculosis, other)						
<b>Fungal targets</b> (Difficult to treat fungi, incl. Scedosporium, Pneumocystis & Candida spp.)						
Parasitic targets (schistosomiasis, other)						

#### BioDiem Future Investment Opportunity

Vaccine market US\$52b by 2016

Anti-infectives market market, US\$103 billion by 2015

Antifungals market, US\$12.2 billion by 2016 Global antibacterials market, US\$46 billion by 2017

## BioDiem BioDiem Limited

Market Cap	\$4.3 M
52 week range	\$0.03 - \$0.10
Cash (at 30 Jun 13)	\$1.2M
Shares	142.1m
Shareholders	890
Listed Options	24.6m

BioDiem will delist from the ASX on 15 November 2013

#### Hugh Morgan AC



Chairman

#### **Julie Phillips**



CEO

#### Prof Larisa Rudenko



Non-executive Director

#### Prof Arthur Li



Non-executive Director

#### **Don Brooks**



#### Non-executive Director

## BioDiem Next 12 months



Additional license revenues



Further clinical trial results



Vector program progress



Continued growth in IP portfolio



Further hepatitis vaccine progress



Sales and use of LAIV in new territories



BDM-I testing results in animal models



Finalisation of BDM-E out-licensing or sale

# BioDiem

## Therapies for major infectious diseases and related cancers

Australia Biotech Invest 2013 : Melbourne 28 October 2013

Julie Phillips, CEO www. biodiem.com (ASX:BDM)